Kiniksa Pharmaceuticals Q4 2025 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy KNSA?
Source: seekingalpha
- Earnings Performance: Kiniksa Pharmaceuticals reported a Q4 2025 GAAP EPS of $0.17, missing expectations by $0.16, indicating a shortfall in profitability that may negatively impact investor confidence.
- Revenue Growth: The company achieved revenue of $202.13 million in Q4, a 65% year-over-year increase, surpassing market expectations by $1.12 million, reflecting strong product demand and promising future growth potential.
- Cash Flow Status: As of December 31, 2025, Kiniksa had $414.1 million in cash and short-term investments with no debt, a significant increase from $243.6 million in 2024, enhancing the company's financial stability.
- Future Outlook: Kiniksa expects 2026 ARCALYST net product revenue to be between $900 million and $920 million, slightly below the consensus of $909.16 million, indicating a cautious outlook on future revenues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KNSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KNSA
Wall Street analysts forecast KNSA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 46.740
Low
48.00
Averages
53.50
High
60.00
Current: 46.740
Low
48.00
Averages
53.50
High
60.00
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kiniksa to Speak at TD Cowen Health Conference
- Conference Participation: Kiniksa Pharmaceuticals International will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 3:10 p.m. Eastern Time, showcasing its latest advancements in the biopharmaceutical sector.
- Live Webcast Details: The presentation will be accessible via a live webcast on Kiniksa's website under the Investors section, ensuring that investors and media can stay updated with the company's latest developments, enhancing transparency and communication efficiency.
- Event Replay Availability: A replay of the event will be available approximately 48 hours after its conclusion, allowing investors and stakeholders who could not attend live to access the information, further improving information accessibility.
- Company Background Overview: Kiniksa is a biopharmaceutical company focused on developing novel therapies to improve patients' lives, particularly in addressing unmet needs in cardiovascular indications, demonstrating its strategic positioning in the biopharmaceutical market.
See More
Kiniksa Pharmaceuticals Q4 2025 Earnings Highlights
- Significant Revenue Growth: Kiniksa Pharmaceuticals reported Q4 2025 ARCALYST product revenue of $202.1 million, reflecting a 65% year-over-year increase, with full-year revenue reaching $677.6 million, indicating strong growth potential in the recurrent pericarditis market.
- Improved Profitability: The company achieved a net income of $14.2 million in Q4 2025, a substantial turnaround from a net loss of $8.9 million in Q4 2024, with a year-end cash balance of $414.1 million, showcasing robust cash flow and financial health.
- Accelerated Market Penetration: ARCALYST's penetration rate among recurrent pericarditis patients increased to 18%, with plans to further expand market share through physician awareness and digital marketing, projecting net revenue for 2026 between $900 million and $920 million.
- R&D Progress on Track: The Phase II clinical trial for KPL-387 is ongoing, with data expected in the second half of 2026, and plans to initiate clinical work on KPL-1161 by year-end, demonstrating the company's continued investment and confidence in its future product pipeline.
See More
Kiniksa Pharmaceuticals Q4 2025 Earnings Report
- Earnings Performance: Kiniksa Pharmaceuticals reported a Q4 2025 GAAP EPS of $0.17, missing expectations by $0.16, indicating a shortfall in profitability that may negatively impact investor confidence.
- Revenue Growth: The company achieved revenue of $202.13 million in Q4, a 65% year-over-year increase, surpassing market expectations by $1.12 million, reflecting strong product demand and promising future growth potential.
- Cash Flow Status: As of December 31, 2025, Kiniksa had $414.1 million in cash and short-term investments with no debt, a significant increase from $243.6 million in 2024, enhancing the company's financial stability.
- Future Outlook: Kiniksa expects 2026 ARCALYST net product revenue to be between $900 million and $920 million, slightly below the consensus of $909.16 million, indicating a cautious outlook on future revenues.
See More
Kiniksa Reports Strong 2025 Financials with 62% Growth in ARCALYST Sales
- Significant Sales Growth: ARCALYST achieved net product revenue of $202.1 million in Q4 2025 and $677.6 million for the full year, reflecting a 62% year-over-year increase, indicating growing market acceptance of IL-1α and IL-1β inhibitors as a second-line treatment for recurrent pericarditis, with 2026 sales expected to reach between $900 million and $920 million, further solidifying market position.
- Robust Financial Profile: By the end of 2025, Kiniksa's cash and short-term investments rose to $414.1 million, a 70% increase from 2024, with no debt, providing strong support for future R&D and market expansion initiatives.
- Clinical Pipeline Advancements: Data from the Phase 2 trial of KPL-387 is expected in the second half of 2026, and the Phase 1 trial of KPL-1161 is planned to start by the end of 2026, which will offer additional treatment options for recurrent pericarditis patients and enhance the company's product portfolio.
- Cost Control in Operations: Total operating expenses for Q4 2025 were $182.4 million, up from $141.8 million in Q4 2024, but the increase was driven by collaboration expenses, indicating improved operational efficiency while expanding the business and effectively managing costs.
See More
Kiniksa Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Kiniksa Pharmaceuticals is set to release its Q4 2023 earnings on February 24 before market open, with a consensus EPS estimate of $0.40, reflecting a substantial year-over-year increase of 433.3%, which could positively impact the stock price.
- Revenue Expectations: The revenue is projected to reach $201.01 million, representing a 64.0% year-over-year growth, indicating the company's increasing market demand and growth potential, which may attract more investor interest.
- Performance Forecast Revisions: Over the past year, Kiniksa has not missed EPS estimates, achieving a 0% miss rate, while it has successfully met revenue estimates 75% of the time, demonstrating stability in revenue performance despite no upward revisions in EPS estimates in the last three months.
- Future Outlook: Kiniksa anticipates net product revenue from ARCALYST to be between $900 million and $920 million by 2026, further enhancing market confidence in its long-term growth potential.
See More
Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth
- Significant Revenue Growth: Kiniksa's ARCALYST net product revenue reached $677.5 million in 2025, up 62% from $417 million in 2024, indicating strong market demand in the cardiovascular treatment sector.
- Optimistic Future Outlook: The company expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million, reflecting confidence in sustained product growth and solidifying its position in the biopharmaceutical market.
- Clinical Trial Progress: Data from the Phase 2 trial of KPL-387 is expected in the second half of 2026, which, if successful, could expand the IL-1α and IL-1β inhibition market, addressing the needs of more patients.
- Strong Financial Position: As of the end of 2025, Kiniksa had $414.1 million in cash and short-term investments, an increase of $170.4 million from the previous year, ensuring ample funding for future R&D and market expansion efforts.
See More
Kiniksa to Speak at TD Cowen Health Conference
- Conference Participation: Kiniksa Pharmaceuticals International will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 3:10 p.m. Eastern Time, showcasing its latest advancements in the biopharmaceutical sector.
- Live Webcast Details: The presentation will be accessible via a live webcast on Kiniksa's website under the Investors section, ensuring that investors and media can stay updated with the company's latest developments, enhancing transparency and communication efficiency.
- Event Replay Availability: A replay of the event will be available approximately 48 hours after its conclusion, allowing investors and stakeholders who could not attend live to access the information, further improving information accessibility.
- Company Background Overview: Kiniksa is a biopharmaceutical company focused on developing novel therapies to improve patients' lives, particularly in addressing unmet needs in cardiovascular indications, demonstrating its strategic positioning in the biopharmaceutical market.
See More
Kiniksa Pharmaceuticals Q4 2025 Earnings Highlights
- Significant Revenue Growth: Kiniksa Pharmaceuticals reported Q4 2025 ARCALYST product revenue of $202.1 million, reflecting a 65% year-over-year increase, with full-year revenue reaching $677.6 million, indicating strong growth potential in the recurrent pericarditis market.
- Improved Profitability: The company achieved a net income of $14.2 million in Q4 2025, a substantial turnaround from a net loss of $8.9 million in Q4 2024, with a year-end cash balance of $414.1 million, showcasing robust cash flow and financial health.
- Accelerated Market Penetration: ARCALYST's penetration rate among recurrent pericarditis patients increased to 18%, with plans to further expand market share through physician awareness and digital marketing, projecting net revenue for 2026 between $900 million and $920 million.
- R&D Progress on Track: The Phase II clinical trial for KPL-387 is ongoing, with data expected in the second half of 2026, and plans to initiate clinical work on KPL-1161 by year-end, demonstrating the company's continued investment and confidence in its future product pipeline.
See More
Kiniksa Pharmaceuticals Q4 2025 Earnings Report
- Earnings Performance: Kiniksa Pharmaceuticals reported a Q4 2025 GAAP EPS of $0.17, missing expectations by $0.16, indicating a shortfall in profitability that may negatively impact investor confidence.
- Revenue Growth: The company achieved revenue of $202.13 million in Q4, a 65% year-over-year increase, surpassing market expectations by $1.12 million, reflecting strong product demand and promising future growth potential.
- Cash Flow Status: As of December 31, 2025, Kiniksa had $414.1 million in cash and short-term investments with no debt, a significant increase from $243.6 million in 2024, enhancing the company's financial stability.
- Future Outlook: Kiniksa expects 2026 ARCALYST net product revenue to be between $900 million and $920 million, slightly below the consensus of $909.16 million, indicating a cautious outlook on future revenues.
See More
Kiniksa Reports Strong 2025 Financials with 62% Growth in ARCALYST Sales
- Significant Sales Growth: ARCALYST achieved net product revenue of $202.1 million in Q4 2025 and $677.6 million for the full year, reflecting a 62% year-over-year increase, indicating growing market acceptance of IL-1α and IL-1β inhibitors as a second-line treatment for recurrent pericarditis, with 2026 sales expected to reach between $900 million and $920 million, further solidifying market position.
- Robust Financial Profile: By the end of 2025, Kiniksa's cash and short-term investments rose to $414.1 million, a 70% increase from 2024, with no debt, providing strong support for future R&D and market expansion initiatives.
- Clinical Pipeline Advancements: Data from the Phase 2 trial of KPL-387 is expected in the second half of 2026, and the Phase 1 trial of KPL-1161 is planned to start by the end of 2026, which will offer additional treatment options for recurrent pericarditis patients and enhance the company's product portfolio.
- Cost Control in Operations: Total operating expenses for Q4 2025 were $182.4 million, up from $141.8 million in Q4 2024, but the increase was driven by collaboration expenses, indicating improved operational efficiency while expanding the business and effectively managing costs.
See More
Kiniksa Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Kiniksa Pharmaceuticals is set to release its Q4 2023 earnings on February 24 before market open, with a consensus EPS estimate of $0.40, reflecting a substantial year-over-year increase of 433.3%, which could positively impact the stock price.
- Revenue Expectations: The revenue is projected to reach $201.01 million, representing a 64.0% year-over-year growth, indicating the company's increasing market demand and growth potential, which may attract more investor interest.
- Performance Forecast Revisions: Over the past year, Kiniksa has not missed EPS estimates, achieving a 0% miss rate, while it has successfully met revenue estimates 75% of the time, demonstrating stability in revenue performance despite no upward revisions in EPS estimates in the last three months.
- Future Outlook: Kiniksa anticipates net product revenue from ARCALYST to be between $900 million and $920 million by 2026, further enhancing market confidence in its long-term growth potential.
See More
Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth
- Significant Revenue Growth: Kiniksa's ARCALYST net product revenue reached $677.5 million in 2025, up 62% from $417 million in 2024, indicating strong market demand in the cardiovascular treatment sector.
- Optimistic Future Outlook: The company expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million, reflecting confidence in sustained product growth and solidifying its position in the biopharmaceutical market.
- Clinical Trial Progress: Data from the Phase 2 trial of KPL-387 is expected in the second half of 2026, which, if successful, could expand the IL-1α and IL-1β inhibition market, addressing the needs of more patients.
- Strong Financial Position: As of the end of 2025, Kiniksa had $414.1 million in cash and short-term investments, an increase of $170.4 million from the previous year, ensuring ample funding for future R&D and market expansion efforts.
See More
